Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects

Summary

The primary objective of this trial is to investigate the safety and tolerability of single rising doses of BI 473494 in healthy male subjects. The secondary objective is the exploration of PK including dose proportionality, and PD of BI 473494 after single dosing.

Timeline

Start

2017-07-27

Primary completion

2017-11-14

Completion

2017-11-14

Outcome

Outcome not reported

Stopped (Business): “Terminated (Business Reasons)”

Drugs

Indications

No indication recorded.